These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26062980)

  • 1. Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.
    Sgambato JA; Park TS; Miller D; Panicker LM; Sidransky E; Lun Y; Awad O; Bentzen SM; Zambidis ET; Feldman RA
    Stem Cells Transl Med; 2015 Aug; 4(8):878-86. PubMed ID: 26062980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.
    Panicker LM; Miller D; Awad O; Bose V; Lun Y; Park TS; Zambidis ET; Sgambato JA; Feldman RA
    Stem Cells; 2014 Sep; 32(9):2338-49. PubMed ID: 24801745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages.
    Serfecz JC; Saadin A; Santiago CP; Zhang Y; Bentzen SM; Vogel SN; Feldman RA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition.
    Panicker LM; Srikanth MP; Castro-Gomes T; Miller D; Andrews NW; Feldman RA
    Hum Mol Genet; 2018 Mar; 27(5):811-822. PubMed ID: 29301038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death.
    Messelodi D; Bertuccio SN; Indio V; Strocchi S; Taddia A; Serravalle S; Bandini J; Astolfi A; Pession A
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.
    Sun Y; Florer J; Mayhew CN; Jia Z; Zhao Z; Xu K; Ran H; Liou B; Zhang W; Setchell KD; Gu J; Grabowski GA
    PLoS One; 2015; 10(3):e0118771. PubMed ID: 25822147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis.
    Furusawa J; Mizoguchi I; Chiba Y; Hisada M; Kobayashi F; Yoshida H; Nakae S; Tsuchida A; Matsumoto T; Ema H; Mizuguchi J; Yoshimoto T
    PLoS Pathog; 2016 Mar; 12(3):e1005507. PubMed ID: 26991425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease.
    Panicker LM; Miller D; Park TS; Patel B; Azevedo JL; Awad O; Masood MA; Veenstra TD; Goldin E; Stubblefield BK; Tayebi N; Polumuri SK; Vogel SN; Sidransky E; Zambidis ET; Feldman RA
    Proc Natl Acad Sci U S A; 2012 Oct; 109(44):18054-9. PubMed ID: 23071332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation.
    Awad O; Panicker LM; Deranieh RM; Srikanth MP; Brown RA; Voit A; Peesay T; Park TS; Zambidis ET; Feldman RA
    Stem Cell Reports; 2017 Dec; 9(6):1853-1867. PubMed ID: 29198828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic delivery of recombinant glucocerebrosidase enzyme-containing extracellular vesicles to human cells from Gaucher disease patients.
    Janpipatkul K; Sutjarit N; Tangprasittipap A; Chaiamarit T; Innachai P; Suksen K; Chokpanuwat T; Tim-Aroon T; Anurathapan U; Jearawiriyapaisarn N; Tubsuwan A; Bowornpinyo S; Asavapanumas N; Chairoungdua A; Bhukhai K; Hongeng S
    Orphanet J Rare Dis; 2024 Oct; 19(1):363. PubMed ID: 39358794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells.
    Awad O; Sarkar C; Panicker LM; Miller D; Zeng X; Sgambato JA; Lipinski MM; Feldman RA
    Hum Mol Genet; 2015 Oct; 24(20):5775-88. PubMed ID: 26220978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.
    Lecourt S; Mouly E; Freida D; Cras A; Ceccaldi R; Heraoui D; Chomienne C; Marolleau JP; Arnulf B; Porcher R; Caillaud C; Vanneaux V; Belmatoug N; Larghero J
    PLoS One; 2013; 8(7):e69293. PubMed ID: 23935976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
    Mucci JM; Suqueli García F; de Francesco PN; Ceci R; Di Genaro S; Fossati CA; Delpino MV; Rozenfeld PA
    Gene; 2013 Dec; 532(2):186-91. PubMed ID: 24076352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of SOX17 in hematopoietic development from human embryonic stem cells.
    Nakajima-Takagi Y; Osawa M; Oshima M; Takagi H; Miyagi S; Endoh M; Endo TA; Takayama N; Eto K; Toyoda T; Koseki H; Nakauchi H; Iwama A
    Blood; 2013 Jan; 121(3):447-58. PubMed ID: 23169777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?
    Santos DM; Tiscornia G
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28430167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
    Lu J; Chiang J; Iyer RR; Thompson E; Kaneski CR; Xu DS; Yang C; Chen M; Hodes RJ; Lonser RR; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21665-70. PubMed ID: 21098288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.
    Srikanth MP; Jones JW; Kane M; Awad O; Park TS; Zambidis ET; Feldman RA
    Stem Cells Transl Med; 2021 Jul; 10(7):1081-1094. PubMed ID: 33656802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells.
    Lin HT; Takagi M; Kubara K; Yamazaki K; Michikawa F; Okumura T; Naruto T; Morio T; Miyazaki K; Taniguchi H; Otsu M
    Stem Cell Res Ther; 2024 Apr; 15(1):106. PubMed ID: 38627844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cell line (INSAi001-A) from a Gaucher disease type 3 patient compound heterozygote for mutations in the GBA1 gene.
    Duarte AJ; Ribeiro D; Santos R; Moreira L; Bragança J; Amaral O
    Stem Cell Res; 2019 Dec; 41():101595. PubMed ID: 31678773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.